Catalyst Biosciences Lands $40,400,000 Series C Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c73a678f-ab17-4733-828b-ccbdaf5ae613&Preview=1 -
Date
12/3/2008 -
Company Name
Catalyst Biosciences -
Mailing Address
260 Littlefield Avenue South San Francisco, CA 94080 -
Company Description
Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of proteases. -
Website
http://www.catalystbiosciences.com -
Transaction Type
Venture Equity -
Transaction Amount
$40,400,000 -
Transaction Round
Series C -
Proceeds Purposes
The financing provides us with several years of funding that will allow us to build our pipeline of Alterase therapeutics including advancing our lead protease, CB 813, an improved factor VIIa product for the treatment of acute bleeding in hemophiliacs, through Phase 1/2 proof-of-concept studies in patients. -
M&A Terms
-
Venture Investor
Essex Woodlands Health Ventures -
Venture Investor
Burrill & Company -
Venture Investor
HealthCare Ventures -
Venture Investor
Johnson & Johnson Development Corporation -
Venture Investor
Morgenthaler Ventures -
Venture Investor
Novartis BioVenture Fund
